InDevR Offers Influenza Titer on Chip® to Enhance Flu Vaccine Development

July 9, 2014 InDevR, a Boulder-based life science company, announced today that it is now offering Titer on Chip as a service for rapid quantification of influenza hemagglutinin protein, the crucial ingredient in flu vaccines. Influenza Titer on Chip (Flu-ToC™) utilizes a panel of subtype-specific and broadly-reactive antibodies that enable reliable quantification of hemagglutinin (HA) despite antigenic drift. Flu-ToC can be used …

Protein Sciences Receives Approval from FDA for 2014/15 Formulation of Flublok® Influenza Vaccine

July 8, 2014 Protein Sciences Corporation announced today that the FDA has approved the Company’s strain change amendment for its seasonal influenza vaccine, Flublok. Every year influenza vaccine manufacturers must receive approval from the Agency for changes they make to the upcoming season’s manufacturing process and product formulation, as the influenza vaccine is adapted annually. Early approval for Flublok will …

Researchers Discover Protein that Could Minimize the Impact of Flu Pandemics

SOCS4 protein shown to minimize the immune systems’ overreaction to the flu. Could this knowledge minimise the impact of flu pandemics? Researchers from the Walter and Eliza Hall Institute of Medical research, Melbourne, have discovered a protein that regulates the production of cytokines. Cytokines are signalling cells, and play an important role in the body’s response to infection or trauma. …

Vaccine makers prep for flu season

Here’s a rundown of the names the CDC has given the green light to this time around: Novartis Yes, this is the same Novartis AG (NVS -0.27%) that had egg on its face back in late October, as we wrote on InvestorPlace, after some vials of its Agrippal and Fluad influenza vaccines were found to have developed clumps in them. …

Presentation download: Successful development of H1N1 vaccine in partnership with key industry stakeholders

The National Health Research Institutes (NHRI) is a non-profit foundation established by the Taiwanese government in 1996. The main objective of the institute is to the enhance  medical research and the improvement of health care in Taiwan. At World Vaccine Congress Asia this year, we had the privileged to have Dr. Pele Chong, Investigator & Director Vaccine Research & Development …

deltaFLU®: the highly differentiated flu vaccine

  The highly differentiated flu vaccine deltaFLU®, developed by AVIR Green Hills Biotechnology, is a tailor-made influenza vaccine generated by reverse genetics. The necessity of preparation for a potential new influenza pandemic remains a widely debated issue among experts in the Vaccines industry. Worldwide on-going influenza research continues to find better ways to prevent, diagnose, and treat seasonal and pandemic …

Potential for another #influenza #pandemic: how should we be prepared?

We cannot ever be sure another influenza pandemic won't hit Europe soon, so better to be prepared this time from having looked at the learnings from past years.   Helmut Walerius from the European Commission Directorate General Health and Consumers Health Threats Unit, joined us at the World Influenza Congress in December 2011 as a speaker to share his views …

#Influenza #vaccine: A new approach to public health research and vaccine research and development

Christian Desaintes, Scientific Officer, DG Research, Health Infectious Diseases at the European Commission joined us at the World Influenza Congress in December 2011 to share his view on how the European Commission is contributing to reduce the negative impact of infectious diseases and epidemics with a special focus on influenza.   In his talk he outlines the key area where …